Johnson & Johnson secures FDA accelerated approval for RYBREVANT FASPRO in head and neck cancer, marking the drug's first expansion beyond non-small cell lung cancer.
The FDA granted accelerated approval on Nov. 5, 2026 for RYBREVANT FASPRO in recurrent/metastatic head and neck cancer, the drug's first indication beyond lung cancer, expanding its commercial potential. It is a genuine regulatory win backed by Phase 1b/2 OrigAMI-4 data, but for a company of JNJ's size a single approval rarely moves the shares materially, and continued approval remains contingent on the Phase 3 OrigAMI-5 confirmatory trial.
On Nov. 5, 2026, the FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody.
It is a positive regulatory milestone and the drug's first approval outside lung cancer, but single drug approvals typically have a modest effect on a large company's stock, and continued approval depends on results of the confirmatory Phase 3 OrigAMI-5 study.
The U.S. FDA has granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO for the treatment of recurrent or metastatic head and neck squamous cell carcinoma. This marks the first indication for the dual-targeted therapy beyond lung cancer, addressing a significant unmet need for patients who have progressed on platinum-based chemotherapy and anti-PD-(L)1 antibodies.
On Nov. 5, 2026, the FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody.
It is a positive regulatory milestone and the drug's first approval outside lung cancer, but single drug approvals typically have a modest effect on a large company's stock, and continued approval depends on results of the confirmatory Phase 3 OrigAMI-5 study.